Millipore Sigma Vibrant Logo

554723 ATRA-BA Hybrid - CAS 1037543-26-2 - Calbiochem

Overview

Replacement Information

Key Specifications Table

CAS #Empirical Formula
1037543-26-2C₃₁H₄₀O₄

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
554723-25MG
Retrieving availability...
Limited Availability
Limited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 25 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewThe differentiation-inducer all-trans-Retinoic Acid (ATRA; Cat. No. 554720) and the histone deacetylase inhibitor (HDI) Butyric Acid (BA; Cat. No. 567430) are incorporated chemically via a benzyl ester linkage into a single more permeant mutual prodrug (MP) to facilitate their cellular uptake and to better synergize their cancer killing potency. The growth inhibitions of PC-3 and MDA-MB-231 by the MP (IC50 = 1.02 and 0.01 µM, respectively) are much superior to those achieved by separate (IC50 = 7.6 and 10.85 µM, respectively, with ATRA; IC50 = 72.44 and >1000 µM, respectively, with BA) or combined dosing of ATRA/BA (55% vs. 30% PC-3 growth inhibition by 10 µM MP vs. co-treatment of 10 µM each of ATRA & BA). At 37°C, VNLG/124 is completely converted to ATRA and BA within an hour in fresh murine plasma, but is otherwise stable for more than 24 hours in the absence of esterase activity in 20 mM PBS.
      Catalogue Number554723
      Brand Family Calbiochem®
      Synonyms4-(Butanoyloxymethyl)phenyl-(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoate, VNLG/124, HDAC Inhibitor XV
      References
      ReferencesGediya, L.K., et al. 2008. J. Med. Chem. 51, 3895.
      Product Information
      CAS number1037543-26-2
      FormYellow solid
      Hill FormulaC₃₁H₄₀O₄
      Chemical formulaC₃₁H₄₀O₄
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥95% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 22-36/37/38-63

      Harmful if swallowed.
      Irritating to eyes, respiratory system and skin.
      Possible risk of harm to the unborn child.
      S PhraseS: 22-26-36-45

      Do not breathe dust.
      In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
      Wear suitable protective clothing.
      In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped with Blue Ice or with Dry Ice
      Toxicity Harmful
      Storage -20°C
      Protect from Light Protect from light
      Protect from Moisture Protect from moisture
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalog Number GTIN
      554723-25MG 04055977193138

      Documentation

      ATRA-BA Hybrid - CAS 1037543-26-2 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      ATRA-BA Hybrid - CAS 1037543-26-2 - Calbiochem Certificates of Analysis

      TitleLot Number
      554723

      References

      Reference overview
      Gediya, L.K., et al. 2008. J. Med. Chem. 51, 3895.

      Technical Info

      Title
      White Paper - The Message in the Marks: Deciphering Cancer Epigenetics
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision28-April-2009 RFH
      Synonyms4-(Butanoyloxymethyl)phenyl-(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoate, VNLG/124, HDAC Inhibitor XV
      DescriptionThe differentiation-inducer all-trans-Retinoic Acid (ATRA; Cat. No. 554720) and the histone deacetylase inhibitor (HDI) Butyric Acid (BA; Cat. No. 567430) are incorporated chemically via a benzyl ester linkage into a single more permeant mutual prodrug (MP) to facilitate their cellular uptake and to better synergize their cancer killing potency. The growth inhibitions of PC-3 and MDA-MB-231 by the MP (IC50 = 1.02 and 0.01 µM, respectively) are much superior to those achieved by separate (IC50 = 7.6 and 10.85 µM, respectively, with ATRA; IC50 = 72.44 and >1000 µM, respectively, with BA) or combined dosing of ATRA/BA (55% vs. 30% PC-3 growth inhibition by 10 µM MP vs. co-treatment of 10 µM each of ATRA & BA). At 37°C, VNLG/124 is completely converted to ATRA and BA within an hour in fresh murine plasma, but is otherwise stable for more than 24 hours in the absence of esterase activity in 20 mM PBS.
      FormYellow solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number1037543-26-2
      Chemical formulaC₃₁H₄₀O₄
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityDMSO (5 mg/ml)
      Storage Protect from moisture
      Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
      Toxicity Harmful
      ReferencesGediya, L.K., et al. 2008. J. Med. Chem. 51, 3895.